Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
about
Interventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapyInterventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for the treatment of oral and oropharyngeal cancers: surgical treatmentInterventions for preventing oral mucositis for patients with cancer receiving treatmentEffect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trialsA novel synthetic compound 3-amino-3-(4-fluoro-phenyl)-1H-quinoline-2,4-dione (KR22332) exerts a radioprotective effect via the inhibition of mitochondrial dysfunction and generation of reactive oxygen species.Oral complications of cancer and cancer therapy: from cancer treatment to survivorship.Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?A unique complication associated with concurrent chemoradiation for the treatment of locally advanced head and neck cancerPharmacological protection from radiation ± cisplatin-induced oral mucositisThe addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.Post-radiation dental index: development and reliabilityThe role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments.Strategies for optimizing the response of cancer and normal tissues to radiation.Prevention and treatment of oral mucositis in patients receiving chemotherapyA systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.Evaluation of current and upcoming therapies in oral mucositis prevention.Salivary gland sparing in the treatment of head and neck cancer.Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?Systematic review of amifostine for the management of oral mucositis in cancer patients.Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy.Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.Survey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers: What Do Institutions Perceive as Evidence?A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244).Late Toxicities after Conventional Radiotherapy for Nasopharyngeal Carcinoma: Incidence and Risk Factors
P2860
Q24235217-A4A23D59-D4D0-4E58-8E6F-002DAFC01684Q24235245-12CB95DB-CF31-409A-A72D-41AD85397352Q24235482-26BCD4CB-D3FD-4DC8-B391-FE8143EAC8C8Q24242951-28235E02-8393-4643-B7E4-6B942A3175F9Q24243046-1E509AD4-FE35-41CC-97E4-25C12B23196FQ28538411-370C6FC2-44DD-4F17-B745-69EAEBB75084Q33822540-54180CE2-C422-4C72-AE4D-6BC0661884A2Q34299445-8F673FD1-E8ED-4047-8E56-5946493C5332Q34782021-09AC2624-9999-45A9-AD9C-35BED59C8FEEQ35180964-AD907EAE-19CE-4E4E-B9C5-A4BA64C7F3FEQ35857066-541A0B36-80A1-4438-9D7C-2073F8A5B9A9Q36823982-AF529DF7-561F-49B1-9F74-356F803E1450Q37259248-C0BDD39D-725C-4CB2-901D-19513EB22F3BQ37408321-18B9E8D7-EFAC-468D-8416-9285F3291E98Q37437083-020512E3-C2B5-480E-852B-004BB433D98DQ37531724-A6F6CA10-890A-4797-A750-58CE9F5F065FQ37605224-4A2D602E-A7A7-4736-BF97-EF0E1A3B86D9Q37718044-C23ED513-C68F-4C16-B960-225D81F60714Q37818225-6A7DB177-3B42-4274-BA06-D7254A1638F9Q37934975-5B30B7A9-CB68-4249-B708-24427A80CE28Q38019401-7FA9FDF5-5A43-4F97-B4FF-F731842CC9DDQ38050986-FC0FA2DB-E9D6-42D9-A738-FDA7E65F2FB4Q38125502-721E6B77-2554-4204-B138-02E79D51447EQ38651513-17A5DB5E-F160-46C0-9C9F-729A4AF5BEDDQ43429878-681459F1-F5A5-43FD-B3DA-9B692BC0F4BBQ47132290-2E469783-B7A2-42BC-895D-2F1C5AA2DE78Q59049234-E761CE10-6C4E-4896-A3A7-DD39C24C1273
P2860
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Intravenous amifostine during ...... bo-controlled phase III study.
@en
Intravenous amifostine during ...... bo-controlled phase III study.
@nl
type
label
Intravenous amifostine during ...... bo-controlled phase III study.
@en
Intravenous amifostine during ...... bo-controlled phase III study.
@nl
prefLabel
Intravenous amifostine during ...... bo-controlled phase III study.
@en
Intravenous amifostine during ...... bo-controlled phase III study.
@nl
P2093
P1476
Intravenous amifostine during ...... bo-controlled phase III study.
@en
P2093
Alain Monnier
Alexander de Vries
Irenaus A Adamietz
Jens Buentzel
Michael Glatzel
Oliver Micke
P304
P356
10.1016/J.IJROBP.2005.08.005
P407
P577
2005-10-21T00:00:00Z